COMPARATIVE EVALUATION OF INTRAVITREAL DICLOFENAC PLUS BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF NAÏVE DIABETIC MACULAR EDEMA: A RANDOMIZED CONTROLLED TRIAL
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: To evaluate the therapeutic effects of intra-vitreal injection Bevacizumab combined with Diclofenac-Na versus intra-vitreal Bevacizumab alone in the treatment of naïve diabetic macular edema.
METHODS: In this prospective, randomized interventional clinical trial, 40 eyes of 40 participants were enrolled for trial conducted at an Ophthalmology department of Qazi Hussain Medical Complex, Nowshera. Twenty eyes each included in the intra-vitreal Bevacizumab and bevacizumab plus diclofenac group via random sampling technique. The main outcome variable was a change in best-corrected visual acuity (BC-VA) in log MAR at 4th, 12th and 24th week. The secondary outcomes included mean change in central subfield thickness (CSFT) of macula and possible injection-related side effects.
RESULTS: Marked improvement in BC-VA was observed in both therapeutic groups (mean change in Log MAR: 0.324±0.411 and 0.562±0.388 for bevacizumab alone and combination group, respectively). The difference in BC-VA change was in favor of combination group; however, the level didn’t achieve statistical significance (p = 0.08). Significant decrease in CSFT was noted in both groups (mean reductions: 178.02 ± 166.42, 214.55 ± 132.65) for bevacizumab and combination, respectively). Comparison of CSFT changes between groups revealed that combination decreased CSFT more than bevacizumab, but the difference was statistically insignificant (p = 0.07). Neither injection related side effects nor any marked change in intraocular pressure was observed in either groups.
CONCLUSION: In diabetic macular edema, superiority of combination therapy over Bevacizumab alone was evident, esp. with regard to structural improvement in macula.
Article Details
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online
(e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010;88(3):279-91. https://doi.org/10.1111/j.1755-3768.2008.01501.x
Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, Battaglia Parodi M. Pharmacological approach to diabetic macular edema. Ophthalmic Res 2014:51(2):88–95. https://doi.org/10.1159/000356693
Arevalo JF. Diabetic macular edema: current management. World J Diabetes 2013:4(6):231-3. https://doi.org/10.4239/wjd.v4.i6.231
Early Treatment Diabetic Retinopathy Study Research Group [EDTRS]. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985:103(12):1796-806. https://doi.org/10.1001/archopht.1985.01050120030015
Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: 2-year results of a double-masked, placebo controlled, randomized clinical trial. Ophthalmology 2006:113(9):1533-8. https://doi.org/10.1016/j.ophtha.2006.02.065
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006:26(9):999-1005. https://doi.org/10.1097/01.iae.0000247165.38655.bf
Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmologica 2010:224(Suppl 1):8-15. https://doi.org/10.1159/000315155
Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, et al. Intravitreal Diclofenac versus intravitreal Bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 2015:35(3):421-8. https://doi.org/10.1007/s10792-014-9967-z
Ghanbari H, Kianersi F, Sonbolestan SA, Abtahi MA, Akbari M, Abtahi ZA, Abtahi SH. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. Int Ophthalmol. 2017 Aug; 37(4):867-874. https://doi.org/10.1007/s10792-016-0335-z
Faghihi H, Yahyapour H, Mahmoudzadeh R, Faghihi S. Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. Med Hypothesis Discov Innov Ophthalmol 2017; 6(3):67-75.
Maldonado RM, Vianna RNG, Cardoso GP, de Magalha˜es AV, Burnier MN Jr. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res 2011:36(8):768-73. https://doi.org/10.3109/02713683.2011.585734
Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, et al. Intravitreal Bevacizumab versus combined Bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008:18(6):941-8. https://doi.org/10.1177/112067210801800614
Schmid KE, Neumaier-Ammerer B, Stolba U, Binder S. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol 2006:244(11):1446-52. https://doi.org/10.1007/s00417-006-0322-6
Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy, vascular endothelial growth factor, cycoloxygenase- 2 and nitric oxide. Curr Pharm Des 2004:10(27):3331-48. https://doi.org/10.2174/1381612043383142
Elbendary AM, Shahin MM. Intravitreal Diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 2011:31(10):2058-64. https://doi.org/10.1097/iae.0b013e31822a042a
Preud’homme Y, Demolle D, Boeynaems JM. Metabolism of arachidonic acid in rabbit iris and retina. Invest Ophthalmol Vis Sci 1985:26(10):1336-42.
Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 1998:39(3):581-91.
Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997:16(4):398-406. https://doi.org/10.1165/ajrcmb.16.4.9115750
Hariprasad SM, Callanan D, Gainey S, He YG, Warren K. Cystoid and diabetic macular edema treated with nepafenac 0.1 %. J Ocul Pharmacol Ther 2007:23(6):585-90. https://doi.org/10.1089/jop.2007.0062
Shimura M, Nakazawa T, Yasuda K, Nishida K. Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther 2007:23(3):284-91. https://doi.org/10.1089/jop.2006.134
Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol 2008:2(4):689-92. https://doi.org/10.2147/opth.s3965
Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventin cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol 2010:88(8):896-900. https://doi.org/10.1111/j.1755-3768.2009.01582.x
Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010:30(2):260-6. https://doi.org/10.1097/iae.0b013e3181b8628e
Reis AC, Vianna RN, Reis RS, Cardoso GP. Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation. Arq Bras Oftalmol 2010:73(4):338-42. https://doi.org/10.1590/s0004-27492010000400007
Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of Diclofenac for treatment of macular edema of various etiologies. Retina 2016: 30(3):509-15. https://doi.org/10.1097/iae.0b013e3181bdfa43